Confirmed Control Closed Transaction verified antifungal treatmentsConsumerConsumer healthcare / OTC pharmaceuticalsdermatologyOTC medicines
Lamisil acquired by Karo Healthcare
Karo Healthcare acquired Lamisil, a consumer healthcare / otc pharmaceuticals brand.
Transaction summary
- Target
- Lamisil
- Acquirer
- Karo Healthcare
- Seller
- Haleon
- Announced
- 2023-08-01
- Geography
- -
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-06-19
- Latest update
- 2026-10-21
Value and multiples
100% enterprise value
Undisclosed
Value not disclosed
Basis: FundComb estimate
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
4.1x
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- The 4.1x revenue multiple comes from FundComb’s comps spreadsheet and is not confirmed by a public source; the price, revenue and period behind it are not stated. Karo Healthcare announced its acquisition of a majority stake in Lamisil from Haleon in 2023.
Source summary
No public source summary has been published for this transaction yet.
Continue your research
Related transaction comps
Same buyer / investor
E45 acquired by Karo Healthcare
2021-12-01 · Confirmed
View transaction → Same sellerChapStick acquired by Suave Brands Company
2024-01-25 · Estimated
View transaction → OTC medicinesViatris OTC business acquired by Cooper Consumer Health
2023-10-01 · Confirmed
View transaction → Consumer healthcare / OTC pharmaceuticalsBoehringer Ingelheim Consumer Healthcare business acquired by Sanofi
2016-06-27 · Estimated
View transaction →